An issue of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) bonds rose 5.1% against their face value during trading on Thursday. The high-yield debt issue has a 5.75% coupon and will mature on January 15, 2022. The bonds in the issue are now trading at $96.06 and were trading at $90.50 last week. Price moves in a company’s bonds in credit markets sometimes predict parallel moves in its stock price.

A number of research analysts recently issued reports on the company. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity set a $17.00 price objective on Endo International and gave the stock a “buy” rating in a report on Friday, March 8th. BidaskClub downgraded Endo International from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. Svb Leerink downgraded Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Finally, Leerink Swann cut Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Fourteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $16.00.

NASDAQ ENDP traded down $0.14 during trading hours on Thursday, hitting $8.40. 1,806,556 shares of the company traded hands, compared to its average volume of 3,429,484. Endo International PLC has a twelve month low of $5.27 and a twelve month high of $18.50. The stock has a market capitalization of $1.88 billion, a PE ratio of 2.91 and a beta of 1.21.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, February 28th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.16. Endo International had a negative return on equity of 337.13% and a negative net margin of 35.00%. During the same period in the previous year, the business earned $0.77 earnings per share. As a group, sell-side analysts forecast that Endo International PLC will post 2.16 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LS Investment Advisors LLC acquired a new stake in shares of Endo International in the fourth quarter valued at approximately $59,000. Neuberger Berman Group LLC bought a new position in shares of Endo International during the third quarter worth approximately $202,000. First Quadrant L P CA bought a new position in shares of Endo International during the fourth quarter worth approximately $92,000. Cim Investment Mangement Inc. bought a new position in shares of Endo International during the third quarter worth approximately $262,000. Finally, Paloma Partners Management Co bought a new position in shares of Endo International during the third quarter worth approximately $341,000. 98.25% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2019/03/14/endo-international-endp-bond-prices-rise-5-1.html.

About Endo International (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.